The Effectiveness of Using E-Cigarettes for Smoking Cessation and Decreasing Risk of Diseases Among Heavy Smokers

NCT ID: NCT05639790

Last Updated: 2023-02-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-01

Study Completion Date

2024-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate effectiveness of using e-cigarettes as harm reduction strategy for smoking cessation and decreasing risk of diseases in heavy smokers. The main questions it aims to answer are:

* Is there any effectiveness of using E-cigarette as a harm reduction strategy for smoking cessation?
* what are the impacts of using E-cigarette on respiratory function and risk of COPD?
* Assess the exposure to harmful and potential harmful constituents (HPHCs) of using E-cigarette

Participants will be randomized into a 6 months single-center, open label trial comparing study outcomes among 2 arms: health counselling, E-cigarette + health counselling. The EC arm will receive EC for 1 month. All 2 arms will receive health counselling from a licensed mental health counselor. After baseline, participants will report their use of combustible cigarette in both arms and EC use in the EC arm every day via online questionnaire in Wechat for behavioral monitoring.

If there is a comparison group: Researchers will compare health counselling group to see if E-cigarrette intervention is an effective way to stop smoking, and if there any change in respiratory function and change in exposure to harmful and potential harmful constituents (HPHCs).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Cessation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Counselling

Health counselling from a licensed mental health counselor

Group Type SHAM_COMPARATOR

Health Counselling

Intervention Type OTHER

Health Counselling from a licensed mental health counselor

Eletronic cigarette

Ad libitum use of electronic cigarettes for 1 month and health counselling from a licensed mental health counselor

Group Type EXPERIMENTAL

Electronic cigarettes + Health Counselling

Intervention Type COMBINATION_PRODUCT

Ad libitum use of electronic cigarettes for 1 month

Health Counselling

Intervention Type OTHER

Health Counselling from a licensed mental health counselor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electronic cigarettes + Health Counselling

Ad libitum use of electronic cigarettes for 1 month

Intervention Type COMBINATION_PRODUCT

Health Counselling

Health Counselling from a licensed mental health counselor

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 60 years old, gender is not limited
* The nicotine dependence test (FNDT) result score is 6-10 points
* Self-reported smoking at least 10 cigarettes a day, and smoking for at least 3 years
* Self-reported no current willingness to quit smoking
* Self-reported difficulty controlling the need to smoke, or smoking while sick in bed
* Must not accepted smoking cessation treatment in the last 3 months according to the self-report
* Must have never tried e-cigarette before
* Must be able to fully understand the purpose, nature and content of the research, and voluntarily sign the informed consent form as a subject
* Must agree and able to communicate well with the researcher, and able to complete the online questionnaire and examination in accordance with the research regulations.

Exclusion Criteria

* Self-reported pregnant or breastfeeding
* Severe disease (defined as an illness or condition that put the patient at risk, interfere the trial results, or affect the patient's ability to participate in the trial judged by the panel)
* Past diagnosis of COPD, lung cancer, pneumoconiosis, bronchiectasis, interstitial lung disease, bronchial asthma, or other restrictive ventilatory disorder
* Living with severe heart, brain, liver, kidney, blood system diseases or malignant tumors
* Moderate-severe renal impairment, or creatinine clearance (CCr) ≤50ml/min
* Phenylpyruvaturia
* Allergic predisposition (be allergic to two or more substances), and is allergic to any of the components in e-cigarettes or e-liquid (e.g., benzoic acid, propylene glycol, glycerin, nicotine, etc.)
* Already been enrolled into a smoking cessation treatment, including but not limited to nicotine replacement therapy (NRT), varenicline, bupropion
* Living with mental illness, a history of chronic alcoholism, drug abuse, or any factor that affects compliance
* Participating in other clinical trials
* Life-threatening condition with a life expectancy less than 1 year
* Researcher believes that it is not suitable to participate in this researcher.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shenzhen Smoore Technology Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SR20221001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Feasibility of Treatment for Vaping Cessation
NCT04317300 WITHDRAWN EARLY_PHASE1